Multiple sclerosis (MS) is a common in¯ammatory disease of the central nervous system. Although the etiology of MS remains unknown, studies in experimental autoimmune encephalomyelitis (EAE) have suggested that foreign molecules, which show molecular mimicry with myelin antigens, may play an important role as causative agents of the human disease. In this study, we investigate the molecular mimicry between the extracellular Ig-like domain of the cow's milk protein butyrophilin (BTN) and the extracellular domain of myelin oligodendrocyte glycoprotein (MOG), a candidate autoantigen in MS. Interestingly, we found that as a result of a non-pathogenic cross-reactivity that is localized to a subdominant region of MOG, treatment of C57BL/6 mice with BTN either before or after immunization with MOG was shown to prevent and also suppress the clinical manifestations of EAE. BTN treatment resulted in a signi®cant reduction in both proliferation and production of T h 1-related cytokines (IFN-g, IL-2, IL-12 and granulocyte macrophage colony stimulating factor) in response to MOG. This speci®c inhibition was consistently associated with an up-regulation in IL-10 secretion. Furthermore, adoptive transfer of BTN-speci®c T cells prior to active immunization with MOG resulted in a transitory reduction of the clinical symptoms. Our results suggest that the clinical improvement associated with BTN treatment involved the combination of both anergy and regulatory cells secreting high levels of IL-10. In conclusion, we show that despite the traditional link between molecular mimicry and pathogenic immune response, environmental agents that share homology with autoantigens may also represent a source of cells with a protective phenotype.
Introduction
Multiple sclerosis (MS) is an in¯ammatory disease of the central nervous system (CNS) that causes demyelination and axonal degeneration resulting in the disruption of neurological functions (1) . MS is considered to be an organ-speci®c autoimmune disorder that involves selective activation of T and B lymphocytes reactive against myelin autoantigens (2, 3) . Although the mechanisms underlying the initiation and progression of MS remain poorly understood, converging lines of evidence suggest that both genetic predisposition and exposure to unde®ned environmental agents proceed synergistically to trigger an autoimmune reaction against CNS myelin antigens (4, 5) . Evidence in favor of this model comes largely from epidemiological family studies that illustrate the lack of complete concordance among monozygotic twins (25± 30%), stressing the role of additional non-genetic variables in the genesis of MS (6) . Infectious organisms, particularly viruses, have been commonly associated with the occurrence of autoimmune disorders (7±9). The pathogenic mechanism by which this potential threat may instigate an autoimmune response remains incompletely de®ned (9) . Nevertheless, due to the high degeneracy of T cell recognition (10±12), the concept of molecular mimicry in which structural similarity is shared by foreign antigens and self-proteins has offered a viable hypothesis to explain the activation of self-reactive speci®c T cells (13, 14) .
In MS, the molecular mimicry hypothesis is supported by the ®nding that antigenic determinants of certain viruses are able to stimulate myelin basic protein (MBP)-speci®c CD4 + T cell clones, presumably based on their structural homology to MBP (15) . Moreover, studies undertaken in experimental autoimmune encephalomyelitis (EAE), an autoimmune CNS disorder broadly studied as an animal model of MS, have also shown that virus sequences that share similarity with myelin autoantigens can trigger a cross-reactivity in vivo that ultimately results in the development of clinical signs of the disease (16, 17) . In contrast, recent studies have shown that certain MBP-mimicking peptides derived from human papilloma virus and Bacillus subtilis were able to protect against EAE by means of cross-reactivity with self-peptide MBP 87±99 (18) . Therefore, the notion that foreign antigens speci®cally interplay with autoaggressive T cells brings forward a new scenario wherein molecular mimicry may also assume a protective role in autoimmune diseases.
Epidemiological and recent experimental studies have raised the possibility that dietary compounds containing proteins that cross-react with myelin antigens may also have a role in the pathogenesis of the disease (19±21). Enhanced T cell reactivity against several cow's milk proteins, such as BSA, has been reported in MS patients (21) . Furthermore, BSA 193±204 was demonstrated to be highly immunogenic in SJL/J mice and probably, as a result of its homology with the exon 2 of MBP, was able to induce clinical signs of EAE in some of these mice (21) . Similarly, based on the homology shared by the extracellular IgV-like domain of butyrophilin (BTN), a major protein of the milk fat globule membrane (22, 23) , and the myelin oligodendrocyte glycoprotein (MOG) (24) , a candidate target for the pathogenic autoimmune response in MS (25, 26) , immunization of Dark Agouti rats with BTN resulted in pathological damage in the CNS (27) . Since the response to MOG in humans appears to be highly heterogeneous, characterized by different immuno-dominances among individuals (28) , it is the purpose of this paper to further evaluate the deleterious and/or protective role of the milk protein BTN in C57BL/6 mice, a strain that is susceptible to MOG-induced EAE. This may, therefore, further characterize the relevance of this structural homology with respect to human disease. Here, we present evidence that the cross-reactivity between the two proteins entails a preventive and protective response against the disease, rather than representing an encephalitogenic menace. Thus, BTN treatment was able to not only prevent EAE by subsequent immunization with MOG, but also ameliorate the clinical manifestations of a pre-existing disease. Furthermore, the underlying mechanisms of this protection appear to be associated with an inhibition of the T h 1 encephalitogenic response to MOG that seems to be mediated by the generation of anergy and/or regulatory T cells.
Methods

Mice
Female C57BL/6 (B6; H-2 b ) and NOD/Lt (H-2 g7 ) mice aged 12±15 weeks, were obtained from the Central Animal House at La Trobe University. All experiments involving animals and their care were performed under an approved protocol in accordance with the Australian code of practice for the care and use of animals for scienti®c purposes (NHMRC, 1997).
Antigens
Recombinant proteins consisting of the N-terminal Ig-like domain of human MOG (amino acids 1±120) and the ®rst Iglike domain of bovine BTN (amino acids 1±115) both containing an N-terminal six histidine tag, were expressed in Escherichia coli M15(pREP4) and puri®ed as described by Ni-NTA super¯ow (Qiagen) chromatography. An alternating organic wash with 60% isopropanol was included for better removal of contaminants as well as endotoxins from the Ni-NTA beads or recombinant protein, as previously described (29) . Eluted proteins were ®lter sterilized (0.2 mm) before stored at ± 20°C until further use. Purity was veri®ed by SDS± PAGE and protein concentration was determined via the BCA protein assay (Pierce). Bacterial endotoxin levels were <0.1 EU/ml as determined by the Limulus amebocyte lysate assay (Sigma, St Louis, MO). The his-tagged ubiquitin glutathione Stransferase (His-Ub-GST) was kindly provided by Dr Rohan Baker and puri®ed as above. Keyhole limpet hemocyanin (KLH) was purchased from Sigma. MOG 35±55 (MEVGWYRSP-FSRVVHLYRNGK) was synthesized by Auspep (Melbourne, Australia). A set of overlapping (by three residues) 15mer MOG peptides covering the extracellular domain molecule of rat MOG (amino acids 1±132) was obtained from Chiron Technologies (Melbourne, Australia).
Induction of EAE and clinical evaluation
EAE was induced by immunizing animals s.c. over two sites in the thigh with either 100 mg of MOG or 150 mg of MOG 35±55 emulsi®ed in an equal volume of complete Freund's adjuvant (CFA; Gibco/BRL) supplemented with Mycobacterium tuberculosis H37 RA (400 mg/mouse; Difco). Pertussis toxin (300 ng; List Biological, Campbell, CA) was injected i.v. at the time of immunization and repeated 48 h later. Animals receiving adjuvant alone served as controls. Mice were assessed daily beginning at day 5 for clinical signs of EAE and were graded according to the following scale: 0, no disease; 1, loss of tail tone; 2; hind limb weakness or partial paralysis; 3 complete hind limb paralysis and body paresis; 4 hind and front limb paralysis; 5 death. Gradations of 0.5 for intermediate scores were assigned to animals exhibiting signs of a lesser severity than any of these stages. 
Pretreatment and treatment with BTN
Adoptive transfer experiments
B6 donors mice were immunized s.c. with 200 mg of either BTN or KLH emulsi®ed in IFA. Twelve days later, their spleens were collected and stimulated in vitro with BTN or KLH (20 mg/ml) in the presence of IL-2 (50 U/ml) for 3 days. Cells were separated on a Ficoll gradient (Amersham Biosciences), resuspended in PBS and 3 Q10 7 splenocytes were injected i.v. via the tail vein of B6 recipient mice. Twenty-four hours after transfer, animals were immunized s.c. with 100 mg of MOG emulsi®ed in CFA followed by 300 mg of pertussis toxin i.v. on days 0 and 2. EAE was scored daily as described above.
Antigen speci®c proliferation assay and cytokine production
To quantify the in vitro proliferative response to antigen, lymph nodes (LN; inguinal, popliteal, axillary and mesenteric) and spleens were obtained 13, 30 and 50 days after EAE induction. Tissues were mechanically homogenized to make a single-cell suspension and cells were seeded in triplicate in 96-well¯at-bottomed plates at a concentration of 1 Q 10 6 cells/ml in RPMI 1640 medium supplemented with 2 mM L-glutamine, 100 mg/ ml streptomycin, 100 U/ml penicillin, 10 mM HEPES, 1 mM sodium pyruvate, 2Q10 ±5 M 2-mercaptoethanol and 5% heatinactivated FCS. Cells were cultured with MOG or BTN (20 mg/ ml), His-Ub-GST (40 mg/ml), concanavalin A (Con A; 2 mg/ml), heat-inactivated Mycobacterium tuberculosis (10 mg/ml) or medium alone in the presence or absence of rIL-2 (200 U/ml). After 48 h of incubation at 37°C with 5% CO 2 and humidi®ed atmosphere, plates were pulsed with [ 3 H]thymidine (1.0 mCi/ well; Amersham Pharmacia Biotech) for an additional 16 h before harvesting the cells. Results are expressed as mean thymidine uptake (c.p.m.) of triplicate cultures. CD4 + T cells were puri®ed by positive selection using CD4 (L3T4) MicroBeads on an autoMACS magnetic separator (Miltenyi Biotech). CD4 + purity was veri®ed by¯ow cytometry and showed >95%. Cytokine production was determined by quantitative capture ELISA according to the supplier's guidelines from 2-ml cultures containing 2 Q 10 6 spleen or LN cells.
Plates were stimulated with no antigen, MOG (30 mg/ml) and Con A (5 mg/ml). Culture supernatants were collected at 24 h to measure IL-2 and IL-4 production or at 48 h for levels of IL-12, IFN-g, granulocyte macrophage colony stimulating factor (GM-CSF), transforming growth factor (TGF)-b and IL-10. All paired mAb used in the assay were from BD PharMingen and cytokine concentrations were calculated using standard curves generated with known amounts of recombinant proteins (Peprotech, Rocky Hills, NJ). Cytokine IL-4 mRNA expression in the spleen and LN cells was detected by RT-PCR using total cellular RNA isolated from 2 Q 10 6 stimulated cells in the presence or absence of the relevant antigen. Total RNA was extracted using TRIzol Reagent (Invitrogen) according to the manufacturer's protocol. RNA samples were reverse transcribed into cDNA with oligo(dT) 20 primer and Superscript II reverse transcriptase (Gibco/BRL). For PCR analysis, equivalent amounts of cDNA were ampli®ed using 2.5 U of Taq DNA polymerase (Gibco/BRL), 1 mM of each dNTP, 50 pmol of each primer, and a PCR buffer mixture containing 50 mM KCl, 10 mM Tris (pH8.3), 1.5 mM MgCl 2 and 0.01% gelatine. The primers used were: b-actin sense 5¢-GGA CTC CTA TGT GGG TGA CGA GG-3¢; antisense 5¢-GGG AGA GCA TAG CCC TCG TAG AT-3; IL-4 sense 5¢-GAG CCA TAT CCA CGG ATG CGA CAA-3¢; antisense 5¢-CAT GGT GGC TCA GTA CTA CGA GTA-3¢. PCR reactions were carried out in a Perkin-Elmer Cetus 9600 Gene amp thermal cycler for 35 cycles (denaturation, 30 s at 94°C, annealing, 30 s at 55°C and elongation for 30 s 72°C). PCR products were resolved on a 1.5% agarose gel containing 0.5 mg ethidium bromide/ml and visualized under UV light.
Assay of antigen-speci®c IgG subclasses
Serum MOG-speci®c IgG subclasses were measured by ELISA. Brie¯y, 96-well Maxisorp microtiter plates were pretreated with 0.2% glutaraldehyde and were coated with 5 mg/ml of MOG in 10 mM carbonate buffer (pH 9.6) for 3 h at 37°C. The plates were washed 5 times with PBS/Tween 20 and then blocked with 2% BSA in 10 mM carbonate buffer (pH 9.6) overnight at 4°C in a humidi®ed chamber. After washing, 100 ml of 1:500 dilution sera, in triplicate, was added to the wells and incubated at 37°C for 1 h. Peroxidase-conjugated anti-rat IgG1, IgG2b and IgG3 (Clonotyping System-HRP; Southern Biotechnology Associates, Birmingham, AL) were added at a ®nal dilution of 1:800 for 1 h at 37°C. The mAb biotinylated anti- mouse IgG2a b (Igh-1 b ) (PharMingen) was used to detect anti-MOG IgG2c in the mouse sera followed by avidin±peroxidase (Sigma) for 30 min at 1:1000 dilution. ABTS was used for the development of the colorimetric reaction and optical density was read in a microplate reader using a 405-nm ®lter. Results were expressed as OD units.
Results
T cell cross-reactivity between MOG and BTN did not result in neurological damage.
In our initial studies, two strains of mice NOD/Lt (H-2 g7 ) and B6 (H-2 b ) highly susceptible to EAE induced by MOG (25) were evaluated for susceptibility to the disease by immunization with BTN. Sensitization of animals with dosages ranging from 50 to 200 mg of BTN in CFA did not result in any clinical signs of EAE. Histopathological examinations of paraf®n-embedded sections from the brain (cerebellum, pons and medulla) and spinal cord (cervical, thoracic and lumbrosacral) of mice (n = 7±9 per group) sacri®ced at day 30 and 55 post-immunization demonstrated no signs of in¯ammation or demyelination as assessed by Hematoxylin & eosin and Luxol fast blue staining (data not shown). Although BTN was not found be encephalitogenic in the strains of mice tested, lymphocytes from BTNimmunized animals responded vigorously to the priming antigen and, more remarkably, also mounted a signi®cant proliferative response to MOG (Table 1) . Concordantly, a marked lymphoproliferative response was elicited by MOGimmunized animals in recall response to BTN, further indicating the mutual cross-reactivity between the two proteins. Splenocytes isolated from MOG and BTN immunized mice did not proliferate in response to the control proteins His-Ub-GST and KLH (SI < 1.1 and SI < 1.15 respectively). As shown in Table 1 , the nature of this cross-reactivity appears to be MHC class II restricted since CD4 + T cells from MOG-immunized animals showed a signi®cant response to BTN in the presence of irradiated antigen-presenting cells. Interestingly, the cytokine pro®le of spleen cells from MOG-primed animals upon stimulation with BTN in vitro strongly differed from the T h 1-type pattern characteristic upon recall response to MOG. Thus, response to BTN signi®cantly inhibited the production of IFN-g, GM-CSF and IL-2, whereas the production of IL-10 was upregulated. We next analyzed the peptide-speci®c proliferation of spleen cells from MOG-and BTN-primed mice using a panel of overlapping synthetic 15mer MOG peptides encompassing the whole extracellular domain of MOG. As seen in Fig. 1 , lymphocytes from MOG-primed mice showed a dominant response to the MOG sequence 37±51, whereas the dominant response of lymphocytes derived from BTN-primed mice was restricted to the MOG sequence 73±87, suggesting that the primary cross-reactivity between the two antigens did not comprise encephalitogenic regions of MOG in H-2 b mice (16, 30) . However, residual cross-reactivity was also found in the MOG sequence 40±54.
BTN protects B6 mice against MOG-induced EAE
Having observed that BTN was recognized by MOG-speci®c T cells in vitro, we next sought to considered whether treatment with the milk protein could possibly modulate the natural course of EAE by interfering with the encephalitogenic MOGspeci®c T cells. Therefore, to investigate whether BTN could confer protection to MOG-induced EAE, groups of eight to 11 mice were treated s.c. with BTN in IFA 1 week prior to challenge with MOG in CFA. Control animals received the unrelated antigen KLH, the vehicle of administration (IFA in saline) or were left untreated before MOG immunization. As shown in Fig. 2 in B6 mice, active immunization with MOG in CFA induces severe paralysis in all of the animals. As opposed to the recently described protective effect of IFA/saline in EAE (31), the clinical symptoms in the vehicle-treated animals or KLH control group were virtually indistinguishable from those exhibited by the untreated group. In contrast, administration of BTN in IFA 1 week before the encephalitogenic challenge resulted in a dramatic reduction of the clinical symptoms with a lower incidence and delayed onset than those of the control groups. Thus, only 33.3% of BTN-pretreated animals developed the disease, while the incidence of EAE in the control groups was 100%. The mean maximal clinical score in the three BTN-pretreated mice that exhibited EAE was 1 T 1.08 as compared to 3.1 T 0.01 in the KLH-pretreated controls, 3.57 T 0.49 in the PBS group and 3.41 T 0.44 in the untreated group. The lower disease severity observed in BTN affected mice was accompanied by a reduction in the number of days of illness that could be attributed to an atypical relapsing-remitting character displayed by these animals, which differed from the single acute episode that follows MOG immunization in B6 mice. The mean day of disease onset of the BTN-pretreated group was also delayed by 3 days in comparison with that of the control groups.
BTN reduces MOG-induced lymphocyte proliferation and alters cytokine responses
To ascertain whether the inhibition of the clinical signs seen in BTN-pretreated mice was associated with an altered response to MOG in the periphery, the ability of LN cells and splenocytes from all of the groups to respond to antigen in vitro was assayed 13 days after the encephalitogenic challenge. As seen in Fig. 3 , LN cells from control animals that received KLH or PBS in IFA proliferated vigorously and to a similar degree in response to MOG. In contrast, lymphocytes isolated from BTN-pretreated animals were signi®cantly less responsive to in vitro re-stimulation with MOG. The lymphoproliferative response to Con A or M. tuberculosis was not affected by the BTN treatment, which con®rms the competence of the T cells populations from BTN-injected mice to respond to non-speci®c stimulation. Comparable results were obtained when the proliferative responses of spleen cells were studied (data not shown).
In order to examine the possibility that a deviation of the characteristic T h 1 phenotype of the pathogenic MOG-speci®c T cells may account for the protection achieved by BTN, cytokine production of stimulated splenic cells from BTNpretreated and control animals was studied in supernatants from cultures set up in parallel with those described above. Spleen cells from mice immunized with BTN, but not with KLH or adjuvant alone, secreted reduced amounts of T h 1-type cytokines (IFN-g, IL-2, IL-12 and GM-CSF) in response to MOG, whereas very high levels of the T h 2 type cytokine IL-10 were readily detected in the same culture supernatants (Table 2) . IL-4 has been reported to be a requisite for the generation and regulation of the T h 2-type immune response (32) . Since levels of this cytokine were undetectable by the ELISA system and in order to further clarify the involvement of the T h 2 subset in the depressed T h 1 response associated with the BTN administration, transcription of IL-4 mRNA was evaluated by semiquantitative RT-PCR. No IL-4 mRNA expression in spleen or LN cells was found in any of the groups (data not shown). There were no signi®cant differences in TGF-b production in all three groups, suggesting that the development of T cell unresponsiveness to MOG in the protected animals was not likely due to T h 3 regulatory cells secreting TGF-b. An analogous pattern of cytokine production was seen 50 days after EAE induction; however, at this time very high levels of IL-10 were also detected in culture supernatants of control mice (Table 2 ). This correlates with the time when the resolution of the acute phase of the disease was seen in the majority of the animals. The lack of IL-10 secretion at the height of clinical disease and the increased levels detected late during the immune response is consistent with the reported regulatory role of IL-10 during clinical recovery (33, 34) .
BTN alters the anti-MOG IgG antibody isotype repertoire
Cytokines are major factors for B cell differentiation (35) as they in¯uence which class or subclass of antibody is produced. Therefore, to address the question of whether the functional change observed in the cytokine pro®le of mice treated with BTN was further accompanied by an altered MOG-speci®c humoral immune response, serum levels of MOG-speci®c IgG subclasses were analyzed by ELISA 50 days after EAE induction with MOG. It can be seen in Fig. 4 that mice pretreated with BTN express anti-MOG IgG1 serum antibodies to a similar level to those of the control groups, whereas their anti-MOG IgG2b and IgG2c levels were markedly reduced. In mice, switching from IgM to IgG2, in particular IgG2a (36, 37) , is thought to be promoted by IFN-g. Interestingly, it has been recently shown that in B6 mice the IgG2a gene is absent, they express instead the closely associated isotype IgG2c (38) . The variation in the amino acid sequences between the two subtypes may therefore reveal dissimilarity of their functional activity. To this end, there is no previous information regarding the role of cytokines in regulating murine IgG2c development. However, the low synthesis of anti-MOG IgG2c antibody exhibited by the protected animals well matched the decreased T h 1 cytokine response described before, supporting the view that IgG2c may also be IFN-g dependent.
Effect of BTN treatment in ongoing EAE
Having seen that pretreatment with BTN was highly ef®cient in preventing mice from development of EAE, we next sought to determine whether treatment with BTN could also ameliorate the clinical manifestations of an established disease in B6 mice. For this purpose, groups of eight mice were immunized with MOG/CFA to develop active EAE. Starting at the time of paralysis (i.e. when animals reached a clinical score b2) mice were treated with a single i.p. injection of BTN, KLH or PBS emulsi®ed in IFA. As can be seen in Fig. 5 , while both control groups (PBS and KLH treated) progressed to developed severe disease, BTN-treated mice promptly recuperated and by the end of the experiment none of the mice showed clinical signs of disease.
Up-regulation of IL-10 and down-regulation of the T h 1 response by BTN treatment
In order to analyze the mechanisms that contribute to the clinical improvement observed in BTN-treated mice, we determined the antigen-speci®c proliferation and the pattern of cytokine secretion in response to MOG in BTN-treated and control groups. As shown in Fig. 6 , there was a signi®cant suppression of the proliferative response to MOG in LN cells of BTN-treated animals as compared to KLH or PBS control groups (similar results were obtained when spleen cells were studied). Treatment with BTN also reduced the production of the T h 1 cytokines IFN-g, GM-CSF, IL-2 and IL-12 in recall response to MOG, whereas the secretion of IL-10 was upregulated (Fig. 7) . Once again, we observed no difference in TGF-b production among groups and there were no detectable levels of mRNA IL-4 expression in spleen or LN from any of the animals. Anti-MOG IgG antibody isotype repertoire was comparable to that attained in the pretreatment experiments (data not shown).
Treatment with BTN induces both anergy and regulatory cells
Because LN and splenic cells from mice that received BTN had a stunted proliferative response and secreted low levels of IL-2 upon stimulation with MOG, we next evaluated whether clonal anergy was induced by BTN administration. To address this issue, we assessed the ability of exogenous IL-2 to rescue anergic T cell responses in vitro. As can be seen in Fig. 6 , addition of 200 U/ml of rIL-2 to the cultures restored the capacity of the LN cells from BTN-treated mice to proliferate in response to MOG (Fig. 6 ). The impaired proliferative response was also restored by rIL-2 when LN cells from BTN-pretreated animals were studied (not shown).
In order to further investigate whether the immune regulation that has originated in the periphery by BTN administration could be adoptively transferred to naive hosts, groups of 20 animals were immunized with BTN, or the control protein KLH, in IFA. On day 12, their spleens were taken and activated in vitro with the priming antigen. Three days later, 3 Q 10 7 splenocytes were transferred into naive animals that were subsequently challenged for EAE induction with MOG. A group of mice that received no cells was also included in this experiment as control for the development of disease. The results in Fig. 8 show that BTN/IFA splenocytes, but not KLH/ IFA cells, transferred protection to actively induced EAE. Protection was limited to 75% of the mice and lasted up to 4 weeks. After that period, two out of the remaining four recipients started to develop signs of the disease with a severity that was almost the same as the no transfer control group, whereas the other two mice remained completely protected throughout the period of observation (Table 3) . Interestingly, recipient animals that received KLH cells exhibited a signi®cant earlier disease onset than the control group that received no cells; there was also an aggravation in the severity of EAE since three of seven mice died within 4 weeks, whereas none of the mice died in the other two groups. As seen in Table 3 , transfer of BTN splenocytes also speci®cally compromises, the ability of MOG-speci®c LN cells to proliferate in vitro. This data supports the hypothesis that speci®c regulatory mechanisms acting on the pathogenic MOG-speci®c population of the recipients may account for the clinical improvement observed.
BTN fails to protect against MOG 35±55 -induced EAE
To obtain further insights into the protective mechanisms induced by BTN, we next determined whether the subtle cross-reactivity identi®ed at the T cell immunodominant level of MOG might also account for the protective role of BTN. For this propose, mice were pre-immunized with BTN in IFA or vehicle alone and 7 days later EAE was induced by immunization with the encephalitogenic peptide MOG 35±55 .
In contrast to what we observed when MOG was used as immunogen, pre-immunization with BTN had no effect on the incidence or severity of EAE actively induced by MOG 35±55 (Fig. 9) , pointing out the importance of the cross-reactivity at the T cell subdominant level of the autoantigen in the generation of the regulatory mechanisms.
Discussion
Although the existence of self-reactive T cells in the normal repertoire of healthy individuals has been extensively described (39±41), the incidence of MS is relatively rare. This clearly indicates that complimentary events may occur to compromise the maintenance of self-tolerance (42) . In this regard, the mimicry hypothesis has long been proposed as a means to explain the instigation and exacerbations of autoimmune disorders (43) . However, our results prompt a holistic interpretation that brings together the protective and the detrimental aspect that the molecular mimicry concept entails. The cow's milk protein BTN, consistent with its shared Table 3 . Protection transferred by BTN-speci®c splenocytes structural similarity to MOG, has been previously described as pathogenic for Dark Agouti rats (27) . However, as we show here in B6 mice, BTN treatment leads to the production of a protective source of regulatory cells that not only prevents, but also suppresses, the autoimmune process induced by MOG. Interestingly, our results appear to indicate that the protective condition associated with BTN treatment could not be explained by means of cross-reactive events at the encephalitogenic core of the autoantigen. Our data shows that the T cell response to BTN cross-reacts primarily with a subdominant region of MOG in B6 mice and this cross-reactivity appears to dictate a subsequent cascade of events that represses the encephalitogenic response to MOG. Interestingly, we observed that although the CD4 + T cell response between BTN and MOG was reciprocally crossreactive, immunization with BTN was unable to induce any clinical or histological signs of EAE in the strains of mice studied. Recent work by Stefferl et al. has shown that BTN immunization induced an in¯ammatory response in the CNS of Dark Agouti rats. Further examination of the cross-reactivity between MOG and BTN unveiled the involvement of an encephalitogenic T cell epitope of MOG (MOG 74±90 ) in the Dark Agouti strain (27) . Our studies undertaken on a B6 background reveal that the cross-reactivity at the T cell level between the two proteins is mostly restricted to the sequence MOG 73±87 and only a minimal response is found within the immunodominant region MOG 35±55 (Fig. 1) . MOG 35±55 (44) and more recently MOG 18±32 (16) have been the only two encephalitogenic epitopes identi®ed in B6 mice. Therefore, it is conceivable that molecular mimicry events not involving the encephalitogenic core of the autoantigen would not initially represent a source of auto-aggressive cells. Thus, these ®ndings provide one line of support for the failure of BTN to induce disease. In addition, immunization with BTN was unable to induce an antibody response that cross-reacts with MOG (Man Ä a Â , unpublished results). To this end, data from previous studies have highlighted the critical role that MOGspeci®c antibodies play in the priming phase of MOG-induced EAE. B cell-de®cient mice are not susceptible to EAE by immunization with MOG (45) and transfer of MOG-speci®c antibodies reverse susceptibility for the disease (46) . The striking shift in the pattern of cytokines released by MOG-primed mouse lymphocytes in response to BTN compared to the characteristic T h 1-type pattern released in recall response to MOG encouraged us to speculate that the crossreactivity between the two proteins could also provide a basis for the suppression of EAE. In fact, this hypothesis has been previously sustained by others, by showing that prevention of EAE could be achieved by pretreatment with certain microbial sequences bearing structural resemblance with an encephalitogenic MBP peptide (18) . The protective effect appeared to rest in the ability of such microbial determinants to behave as altered peptide ligands. Accordingly, pretreatment with BTN and treatment at the disease onset was carried out in B6 mice immunized with MOG. In both settings, protection against the disease was readily obtained and was correlated with a decrease in MOG-speci®c T cell proliferation and a depressed T h 1 response, as evidenced by reduced antigen-speci®c secretion of IFN-g, IL-2, IL-12 and GM-CSF. Previous studies have shown that injection of autoantigens or cross-reactive peptides in IFA prevents EAE (18, 47) . Several mechanisms including suppressor cells (48) , anergy (49) , exhaustion (47) and, particularly, T h 2 immune deviation (50) have been associated with such protective effect. Interestingly, the protection imparted by BTN was not associated with an upregulation in the expression of IL-4 at any time point studied, therefore arguing against T h 2 immune deviation as the protective mechanism that would explain the clinical improvement observed. However, the reduced proliferation and decreased IL-2 secretion in response to antigen and the ®nding that addition of exogenous IL-2 could revert the unresponsiveness state of MOG-speci®c population appears to indicate that T cell anergy was at least one of the mechanisms accountable for the protection. One of the major effects associated with the BTN administration was the consistent up-regulation of IL-10 secretion. Recent investigations have made a connection between anergy and IL-10. IL-10 prevents dendritic cell maturation and thus the stimulation of CD4 + T cells by immature dendritic cells favors the development of anergy (51) . Moreover, high levels of this cytokine promote the expansion of a T cell population that secretes IL-10, but exhibits low proliferative response (52) . It is, therefore, likely that the protective effect provided by BTN may account for the generation of regulatory cells that upon stimulation with MOG display high levels of IL-10, thereby in¯uencing the remaining MOG-speci®c population, which probably harbors precursor and/or effector pathogenic MOGspeci®c T cells. In support of this hypothesis, IL-10 is believed to function as a regulatory cytokine in EAE. IL-10-de®cient mice develop a more severe form of EAE than wild-type mice, and this enhanced response has been shown to be associated with an up-regulation of IFN-g and tumor necrosis factor-a secretion (53) . The regulatory role of IL-10 in our setting was further evidenced by the enhanced IL-10 production exhibited by the untreated mice during the remission phase of the disease ( Table 2 ). The latter observation is compatible with the ®nding that IL-10-de®cient mice also lose the spontaneous recovery from EAE (34) . Taken together, these data suggest that the increased levels of IL-10 during remission appear to be an inherent property of MOG-induced EAE.
To further characterize the regulatory phenotype of BTNspeci®c cells, splenocytes from BTN-primed mice were expanded in vitro and injected into naive recipients prior to MOG immunization. Interestingly, transfer of a syngeneic BTNspeci®c population into naive animals provides signi®cant protection against actively induced EAE. It should be noted that although the protective state was regarded as transient when compared with the protection achieved by the active administration of the protein, the immunological studies revealed that transfer of such regulatory cells induced a considerable effect in the MOG-speci®c repertoire of recipients mice, thus supporting the regulatory role that BTNspeci®c cells play in MOG-induced EAE.
The striking observation that BTN was also ef®cient at suppressing an established disease suggests that the maintenance of the encephalitogenic response was also affected by the milk protein administration. Although it is reasonable to suggest that the regulatory mechanisms that originated in the periphery by BTN treatment may compromise the continuous in¯ux of active T cells into the CNS, we cannot rule out the possibility that regulatory mechanisms may also arise at the site of in¯ammation, as it has been previously described (54) . Thus, the protection achieved by BTN in the setting of an established disease may re¯ect the ability of these regulatory cells to home to sites of in¯ammation where, by revealing its immunomodulatory functions, it may assist to arrest the local in¯ammatory environment. In this context, it has been shown that delivery of IL-10 within the CNS induces down-regulation of the microglia/macrophage functions (55) , which are believed to play a critical role in the effector phase of EAE (56±58). In addition, the ability of the regulatory cells to enter the CNS would be facilitated by the chemokine milieu (59, 60) and by the disruption of the blood±brain barrier during EAE (61, 62) .
Since the cross-reactivity between BTN and MOG involved primarily a subdominant region of MOG in B6 mice (Fig. 1) , we set out to evaluate whether the occurrence of such crossreactivity denotes a mandatory phenomenon for the instigation of regulatory mechanisms associated with the BTN treatment. Under these circumstances, one would presume that protection provided by BTN could, in principle, re¯ect a collateral suppression of the response to the encephalitogenic determinants of MOG in our model. In fact, our results appear to support that hypothesis, as by using MOG 35±55 to induce EAE the administration of BTN/IFA prior challenge had no effect upon disease incidence or severity. This observation suggests that immunization with BTN probably engenders the expansion of regulatory clones that cross-react with the sequence MOG 73±87 and these in essence are primarily responsible for the inhibition of the disease induced by MOG.
Taken collectively, our results highlight the importance of the cross-reactivity between environmental agents and determinants of endogenous proteins that, although not included in the immunodominant core, can generate regulatory cells capable of modulating an autoimmune process. For this, we believed that molecular mimicry is a framework that entails more than autoimmunogenic dominant peptides, and the analysis of another possible cross-reactivity could be useful for achieving a better and comprehensive understanding of the complex interplay between molecular mimicry and autoimmunity. 
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